CD164

Across TCGA pan-cancer cohorts, CD164 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD164 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CD164 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD164 expression acts as an unfavorable survival marker.

LUAD, SARC, and PRAD are the cancer types where CD164 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	IV	0.342	0.893	<.001	12	view →
SARC	OS	Median	All	0.022	0.861	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CD164–LUAD (DFS)

Open the LUAD breakdown →